Biotech may be poised for “big year”
Biotechnology is poised for a boom year in 2004, wrapping up 2003 with a strong recovery and plenty of reason for optimism, in the forecast of G. Steven Burrill, chief executive officer of the San Francisco-based life sciences merchant bank, Burrill & Co.
Corporate lawyers haven’t had much to celebrate since the Internet bubble burst, but a recent stock market run on life sciences companies is breathing new buoyancy into some practices.
When Patents Persist
What if that patent you’re paying royalties on suddenly gets extended? Have you negotiated the best licensing deal possible?
Amgen’s Cannibalistic Ways
If you don’t think that Amgen is excited about its future, check out what the company is piling on its plate. The biotech giant will be earmarking half of next year’s revenue to launch a $5 billion share buyback.
FDA Chief Eyes Path for Copycat Biotech Drugs
Food and Drug Administration Commissioner Mark McClellan said on Friday it may be justifiable for regulators to approve generic forms of biotech drugs even if they have not been through the same lengthy clinical trials required of the original drugs.
Boston’s Biotech Moment
The future is moving out of dusty library stacks and into pristine laboratories on both sides of the Charles River, making this area the national leader in biotechnology. The boom is driven by a new breed of intellectual wearing a white lab coat and using science to breach the barrier between academia and commerce.
Professor, Biotech Butt Heads
Ignacio Chapela, an ecologist known for his controversial research on genetically modified corn, is turning a career setback into a call for action among scientists opposed to the influence of corporate interests on academic research.
Chapela, who was denied tenure last month at the University of California at Berkeley, is now accusing the institution of trying to please the biotech industry by shutting him out.
Tech Transfer: The Ties That Bind
Did you know that the lack of an IPO window, depressed market conditions and a downturn in venture financing affect not only companies but also universities? That’s because so many academic institutions are tied to the fortunes of companies, both small and large, through their technology transfer agreements.
Drug companies make patent concessions
AIDS activists hailed a breakthrough agreement with two of the largest drug companies in South Africa Wednesday, saying it will help more poor people get vital medicines. They cited the Canadian government’s decision to override patent law for essential drugs for Africa as one key factor in persuading the pharmaceutical makers to loosen their hold on patents.
Dutch Official Calls on Europe to Open Markets to Biotech Foods
Europe should no longer exclude genetically modified agricultural products from the U.S., in the view of Economic Affairs Minister Laurens-Jan Brinkhorst. ‘The U.S. rightly complains about trade barriers,’ he said yesterday in The Hague during a University of Leiden meeting.